首页> 外文期刊>Cells >H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy
【24h】

H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy

机译:H3K18AC作为癌症进展的标志性和抗癌治疗的潜在目标

获取原文
           

摘要

Acetylation and deacetylation are posttranslational modifications (PTMs) which affect the regulation of chromatin structure and its remodeling. Acetylation of histone 3 at lysine placed on position 18 (H3K18Ac) plays an important role in driving progression of many types of cancer, including breast, colon, lung, hepatocellular, pancreatic, prostate, and thyroid cancer. The aim of this review is to analyze and discuss the newest findings regarding the role of H3K18Ac and acetylation of other histones in carcinogenesis. We summarize the level of H3K18Ac in different cancer cell lines and analyze its association with patients’ outcomes, including overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS). Finally, we describe future perspectives of cancer therapeutic strategies based on H3K18 modifications.
机译:乙酰化和脱乙酰化是影响染色质结构的调节的后期改性(PTM)和重塑。在放置在18位(H3K18Ac)的赖氨酸时组蛋白3的乙酰化在推动许多类型癌症的进展中起重要作用,包括乳腺癌,结肠,肺,肝细胞,胰腺,前列腺和甲状腺癌。本综述的目的是分析和讨论关于H3K18AC和致癌物中其他组蛋白的乙酰化的最新结果。我们总结了不同癌细胞系中H3K18Ac的水平,并分析其与患者结果的关系,包括整体存活(OS),无进展生存(PFS)和无病生存(DFS)。最后,根据H3K18修改,我们描述了癌症治疗策略的未来视角。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号